FDA Drug Recalls

Recalls / Class II

Class IID-0463-2021

Product

Meloxicam Tablets, USP 7.5 mg 100 Tablets Rx Only NDC 69097-158-07 Manufactured for: Cipla USA, Inc. 9100 S. Dadeland Blvd., Suite 1500 Miami, FL 33156

Brand name
Meloxicam
Generic name
Meloxicam
Active ingredient
Meloxicam
Route
Oral
NDCs
69097-158, 69097-159
FDA application
ANDA077929
Affected lot / code info
KA03034

Why it was recalled

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Recalling firm

Firm
Cardinal Health Inc.
Manufacturer
Cipla USA Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
7000 Cardinal Pl, N/A, Dublin, Ohio 43017-1091

Distribution

Quantity
576 bottles
Distribution pattern
FL, GA, SC

Timeline

Recall initiated
2021-03-15
FDA classified
2021-05-24
Posted by FDA
2021-06-02
Terminated
2024-06-17
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0463-2021. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Meloxicam · FDA Drug Recalls